Ensuring adherence: In the Indian pharmaceutical industry
Companies that produce substandard pharmaceuticals must confront repercussions
Introduction
The Indian pharmaceutical sector, often lauded as the ‘Pharmacy of the World,’ stands at a critical juncture. While its role in supplying affordable generic medicines globally is undeniable, recurring incidents of substandard and contaminated drugs have cast a long shadow over its reputation. The challenge is not merely about adhering to standards but about cultivating a deeply embedded culture of quality and accountability. For India to realize its ambition of becoming a $130 billion industry by 2030 and to uphold the ideal of Atmanirbhar Bharat, a robust and uncompromising compliance framework is not just desirable, but essential.
A primary dimension of this challenge lies in the fragmented and outdated regulatory landscape. The foundational law, the Drugs and Cosmetics Act of 1940, is ill-equipped to handle the complexities of the modern pharmaceutical industry, which now includes sophisticated clinical trials and complex biological products. Enforcement is further complicated by overlapping jurisdictions between the Central Drugs Standard Control Organisation (CDSCO) and state drug control departments, leading to inconsistent implementation of regulations. This structural weakness is evident in the repeated failure to make crucial guidelines—such as those for drug recalls and good distribution practices—legally binding, a lapse that has been highlighted for decades.
The most visible consequence of regulatory laxity is the persistent issue of quality control failures. Recent tragedies, such as the deaths of children linked to contaminated cough syrups containing industrial solvents like diethylene glycol (DEG), underscore the grave risks to public health. Investigations into such cases often reveal non-compliance with Good Manufacturing Practices (GMP) and the use of non-pharmacopoeial grade raw materials. In response, the government has mandated compliance with the revised Schedule M norms, which align India’s GMP standards more closely with international benchmarks like those of the WHO. However, with the compliance deadline extended, the urgency of hawk-like monitoring and surprise inspections cannot be overstated; action after fatalities occur is indefensible.
Compounding the quality concerns are ethical deficits in marketing and promotional activities. For years, the industry operated under a voluntary code for marketing practices, which lacked enforceability. This led to unethical practices, including offering gifts and other inducements to healthcare professionals to promote specific drugs. To address this, the government has introduced the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, making it mandatory for companies to adhere to ethical standards. This new code aims to regulate interactions with healthcare professionals, the provision of drug samples, and claims made about products, thereby fostering a more transparent and ethical ecosystem.
The implications of non-compliance are both domestic and global. Internationally, quality lapses tarnish India’s reputation as a reliable drug supplier, leading to increased scrutiny and the risk of stricter import restrictions from regulatory bodies like the US Food and Drug Administration (FDA). Domestically, they erode public trust and endanger lives. The flagging of over 50 common medications, including paracetamol and vitamin supplements, as “Not of Standard Quality” by the CDSCO is a stark reminder of the scale of the problem.
The way forward requires a multi-pronged and determined approach. First, there is an urgent need to overhaul the colonial-era drug laws and establish a unified, empowered central drug authority with clear lines of command and accountability. Second, the revised Schedule M and UCPMP must be implemented with unwavering strictness, with severe penalties for non-compliance to create a credible deterrent. This requires augmenting the capacity of regulatory bodies with more inspectors, better technology, and advanced testing laboratories.
Ultimately, ensuring compliance is a shared responsibility. While the government must lead with decisive regulatory reform, the pharmaceutical industry must move beyond a mindset of mere compliance to one of proactive quality stewardship. Fostering a culture where patient safety is paramount is crucial for the long-term health of both the population and the industry itself. Only then can the ‘Pharmacy of the World’ be a title of unwavering trust and quality.
UPSC mains exam question based on the provided topic:
GS Paper 2: Governance, Constitution, Polity, Social Justice
- Issues relating to the development and management of the Social Sector/Services relating to Health.
- Government policies and interventions for development in various sectors and issues arising out of their design and implementation. Statutory, regulatory, and various quasi-judicial bodies.
GS Paper 3: Technology, Economic Development, Biodiversity, Environment, Security, and Disaster Management
- Indian Economy and issues relating to planning, mobilization of resources, growth, development, and employment.
- Effects of liberalization on the economy, changes in industrial policy, and their effects on industrial growth.
GS Paper 4: Ethics, Integrity, and Aptitude
- Ethical concerns and dilemmas in government and private institutions.
- Corporate Governance.
- Public/Civil service values and Ethics in Public Administration: Status and problems.
Question 1. Critically analyse the regulatory challenges hindering the quality and compliance standards within the Indian pharmaceutical sector. In light of recent government interventions like the revised Schedule M norms and the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), discuss the steps needed to build a robust and accountable drug regulation framework. (250 words, 15 marks)
Question 2. The reputation of the Indian pharmaceutical industry as the ‘Pharmacy of the World’ is increasingly threatened by issues of quality control and unethical practices. Discuss the socio-economic and ethical implications of these compliance failures. What comprehensive measures, extending beyond mere legal reforms, are required to foster a culture of quality and patient safety in the sector? (250 words, 15 marks)
(Source – The Hindu)
